Adwitiya Kar1, Bolin Liu2, Arthur Gutierrez-Hartmann3,4,5. 1. Cancer Biology Graduate Program, University of Colorado Anschutz Medical Campus, Aurora, CO, U.S.A. 2. Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, U.S.A. 3. Cancer Biology Graduate Program, University of Colorado Anschutz Medical Campus, Aurora, CO, U.S.A. a.gutierrez-hartmann@UCDenver.edu. 4. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, U.S.A. 5. Department Biochemistry & Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, U.S.A.
Abstract
BACKGROUND/AIM: ESE-1/Elf3 controls transformation properties in mammary epithelial cells, and is most clinically relevant in HER2+ breast cancer. Herein we showed that ESE-1 knockdown inhibits tumorigenic growth in HER2+, trastuzumab-resistant HR20 (derived from HER2+ ER+ BT474) and Pool2 (derived from HER2+ ER- SKBR3 cells) cell lines. MATERIALS AND METHODS: We used cell proliferation, clonogenicity, viability, and soft agar assays to measure the effects of ESE-1 knockdown in cell lines. RESULTS: ESE-1 knockdown in the resistant cell lines inhibited HER2 and other downstream effectors in a cell-type specific manner, but caused down-regulation of pAkt and cyclin D1 in both sublines. In parental BT474 and SKBR3 ESE-1 silencing revealed a potent anti-proliferative effect that mimics the trastuzumab-mediated growth inhibition but did not enhance trastuzumab sensitivity in the resistant sublines. CONCLUSION: This study provides rationale to study ESE-1 as a novel mean to treat HER2+ patients who show resistance to anti-HER2 therapy. Copyright
BACKGROUND/AIM: ESE-1/Elf3 controls transformation properties in mammary epithelial cells, and is most clinically relevant in HER2+ breast cancer. Herein we showed that ESE-1 knockdown inhibits tumorigenic growth in HER2+, trastuzumab-resistant HR20 (derived from HER2+ ER+ BT474) and Pool2 (derived from HER2+ ER- SKBR3 cells) cell lines. MATERIALS AND METHODS: We used cell proliferation, clonogenicity, viability, and soft agar assays to measure the effects of ESE-1 knockdown in cell lines. RESULTS:ESE-1 knockdown in the resistant cell lines inhibited HER2 and other downstream effectors in a cell-type specific manner, but caused down-regulation of pAkt and cyclin D1 in both sublines. In parental BT474 and SKBR3ESE-1 silencing revealed a potent anti-proliferative effect that mimics the trastuzumab-mediated growth inhibition but did not enhance trastuzumab sensitivity in the resistant sublines. CONCLUSION: This study provides rationale to study ESE-1 as a novel mean to treat HER2+ patients who show resistance to anti-HER2 therapy. Copyright
Authors: Richard M Neve; Bauke Ylstra; Chuan-Hsiung Chang; Donna G Albertson; Christopher C Benz Journal: Oncogene Date: 2002-05-30 Impact factor: 9.867
Authors: Sara A Hurvitz; Fabrice Andre; Zefei Jiang; Zhimin Shao; Max S Mano; Silvia P Neciosup; Ling-Min Tseng; Qingyuan Zhang; Kunwei Shen; Donggeng Liu; Lydia M Dreosti; Howard A Burris; Masakazu Toi; Marc E Buyse; David Cabaribere; Mary-Ann Lindsay; Shantha Rao; Lida Bubuteishvili Pacaud; Tetiana Taran; Dennis Slamon Journal: Lancet Oncol Date: 2015-06-16 Impact factor: 41.316
Authors: Kristin L Eckel; John J Tentler; Gerald J Cappetta; Scott E Diamond; Arthur Gutierrez-Hartmann Journal: DNA Cell Biol Date: 2003-02 Impact factor: 3.311
Authors: Shom Goel; Qi Wang; April C Watt; Sara M Tolaney; Deborah A Dillon; Wei Li; Susanne Ramm; Adam C Palmer; Haluk Yuzugullu; Vinay Varadan; David Tuck; Lyndsay N Harris; Kwok-Kin Wong; X Shirley Liu; Piotr Sicinski; Eric P Winer; Ian E Krop; Jean J Zhao Journal: Cancer Cell Date: 2016-03-14 Impact factor: 31.743
Authors: Xiaoping Huang; Lizhi Gao; Shuiliang Wang; James L McManaman; Ann D Thor; Xiaohe Yang; Francisco J Esteva; Bolin Liu Journal: Cancer Res Date: 2010-01-26 Impact factor: 12.701